Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Cell Death Dis. 2018 Feb 15;9(3):282. doi: 10.1038/s41419-018-0278-6.
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment surrounding the neoplastic foci. The intricate net of cross-interactions occurring between tumor components, stromal and immune cells leads to an ineffective anergic status favoring the evasion from the host's defenses. Our goal is hereby to trace the road imposed by solid tumors to CAR-T cells, highlighting pitfalls and strategies to be developed and refined to possibly overcome these hurdles.
采用重编程 T 细胞的实体瘤过继细胞疗法可以被视为癌症标志的“下一代”。CAR-T 细胞在实体肿瘤中的疗效不如在液体肿瘤中那么有效，因为它们无法到达和在肿瘤病灶周围的微环境中存活。肿瘤成分、基质和免疫细胞之间发生的错综复杂的交叉相互作用网络导致无效的无能状态，有利于逃避宿主的防御。我们的目标是在此追踪实体肿瘤对 CAR-T 细胞施加的影响，强调可能需要开发和完善的陷阱和策略，以克服这些障碍。
